Log in to search using one of your social media accounts:

 

WakeMed partnership expands new cancer treatment availability
A new partnership between WakeMed Health& Hospitals and Charlotte-based HIFU Prostate Services has expanded the availability of a cancer treatment. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 2, 2017 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

SonaCare highlights Medicare payment hike for HIFU
High-intensity focused ultrasound (HIFU) developer SonaCare Medical said that...Read more on AuntMinnie.comRelated Reading: SonaCare points to new Medicare HIFU reimbursement code SonaCare debuts international HIFU prostate registry New HIFU center launches in Ohio SonaCare, Invivo team up for HIFU ablation tracking SonaCare lands FDA nod for HIFU system (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 21, 2017 Category: Radiology Source Type: news

Edap submits new FDA 510(k) for Focal One HIFU
Edap (NSDQ:EDAP) said today it submitted a new FDA 510(k) application for its next-gen high-intensity focused ultrasound Focal One device designed to treat prostate cancer after withdrawing its previous application in July. The new application alllowed the France-based company to include a new set of clinical data, which it had decided to include following “advanced discussions” with the FDA earlier this year. “The new 510k review may be more efficient as the updates only pertain to the clinical section which includes new studies from active and academic Focal One centers in Europe. Our regulato...
Source: Mass Device - September 12, 2017 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance Ultrasound EDAP TMS SA Source Type: news

SonaCare Medical Delivers Compatability With bkFusion
CHARLOTTE, N.C., Aug. 30, 2017 -- (Healthcare Sales & Marketing Network) -- SonaCare Medical, the leading developer and manufacturer of high intensity focused ultrasound (HIFU) technologies, announces today the successful collaboration with BK Ultrasound,... Devices SonaCare Medical, Sonablate, BK Ultrasound, HIFU (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 30, 2017 Category: Pharmaceuticals Source Type: news

Theraclion highlights HIFU research for Graves' disease
Therapeutic ultrasound technology developer Theraclion is pointing to a clinical...Read more on AuntMinnie.comRelated Reading: Theraclion's Echopulse wins IDE from FDA (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 30, 2017 Category: Radiology Source Type: news

MR-HIFU is kid-safe for osteoid osteoma
MR-guided high-intensity focused ultrasound (MR-HIFU) appears to provide safe,...Read more on AuntMinnie.comRelated Reading: New trial will assess MR-HIFU, chemo drug combo DC docs use MR-HIFU to treat bone tumor FDA approves Philips, Celsion HIFU study (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 25, 2017 Category: Radiology Source Type: news

Profound Medical raises $8m for urology, women ’ s health devices
Profound Medical (TSX:PRN) said today that it inked an $8 million “bought” deal” financing with a pair of underwriters that it plans to use for its Tulsa-Pro and Sonalleve ablation devices. The funding, by Echelon Wealth Partners and  CIBC Capital Markets, involved 10 million units at 80¢ (C$1 ) apiece, consisting of a stock share and a half of a 36-month warrant priced at $1.12 (C$1.40), the Toronto-based company said. The deal also includes a 30-day over-allotment option for another 1.5 million shares, which if exercised would push the gross proceeds to $9.2 million (C$11.5 million). Prof...
Source: Mass Device - August 25, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Urology Wall Street Beat Women's Health Profound Medical Inc. Source Type: news

Study shows incisionless surgery with MR-HIFU effective in destroying painful bone tumors
(Children's National Health System) Doctors from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System have completed a clinical trial that demonstrates how osteoid osteoma, a benign but painful bone tumor that commonly occurs in children and young adults, can be safely and successfully treated using an incisionless surgery method called magnetic resonance-guided high-intensity focused ultrasound. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 24, 2017 Category: International Medicine & Public Health Source Type: news

Hybrid modalities disappoint in bone metastases accuracy
Despite the apparent technological advantages of SPECT/CT, PET/CT, and PET/MRI,...Read more on AuntMinnie.comRelated Reading: ASTRO updates guidelines on painful bone metastases PET/CT CAD finds common spinal metastases PET/MRI detects distant metastasis of breast cancer DC docs use MR-HIFU to treat bone tumor FDG-PET/MRI shows advantages with malignant bone lesions (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 21, 2017 Category: Radiology Source Type: news

Profound Medical closes $6m Philips Sonalleve MR-HIFU biz buy
Profound Medical (TSX:PRN) said today it closed its $6 million acquisition of Royal Philips (NYSE:PHG) Sonalleve MR-HIFU business Philips Sonalleve MR-HIFU platform features real-time MR imaging and thermometry alongside high intensity focused ultrasound for incision-free ablation of tissue, Toronto-based Profound Medical said. “This transaction with Philips is truly transformative for Profound, and represents an opportunity for us to immediately transition from a development-stage to a growth-stage company,. From a commercial perspective, our strengthened MR-Ultrasound ablation technology platform not only...
Source: Mass Device - August 1, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Imaging Mergers & Acquisitions Profound Medical Inc. royalphilips Source Type: news

EDAP submits FDA 510(k) for Ablatherm Fusion HIFU device
Edap (NSDQ:EDAP) said this week it submitted an FDA 510(k) application for its next-gen Ablaterm Fusion device. The Lyon, France-based company’s next-generation Ablatherm Fusion is a robotic high-intensity focused ultrasound device designed to allow urologists to import pre-treatment diagnostic info, including MRI images and 3D biopsy maps, and merge them with live ultrasound images during prostate tissue ablation procedures. The device features the company’s proprietary fusion algorithm, and is designed to be used with its existing range of HIFU devices. “As recently mentioned, the next generation o...
Source: Mass Device - August 1, 2017 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Imaging Oncology Regulatory/Compliance EDAP TMS SA Source Type: news

No License: HIFU Prostate Cancer Doc Arrested No License: HIFU Prostate Cancer Doc Arrested
Dr Ronald Wheeler has repeatedly been in the news for his prostate cancer diagnosis and treatment beliefs and methods.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 25, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Philips posts imaging sales gain in Q2
Royal Philips said that its Diagnosis and Treatment segment, which includes...Read more on AuntMinnie.comRelated Reading: Philips to acquire imaging software firm TomTec Philips partners on CT dose management initiative Philips, Varian, IBA partner on Singapore cancer center Philips to move MR-HIFU business to Profound Philips buys catheter developer CardioProlific (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 24, 2017 Category: Radiology Source Type: news

Philips to acquire TomTec ’ s imaging software
Royal Philips (NYSE:PHG) said yesterday that it agreed to acquire TomTec Imaging Systems and its intelligent image analysis software for an undisclosed amount. Munich-based TomTec makes multi-modality and vendor-neutral diagnostic and analysis applications for cardiology, radiology and OB/GYN, the Dutch healthcare conglomerate said. Founded in 1990, TomTec employs more than 100 workers in the U.S., Europe and Asia. Philips said it plans to continue to offer the acquisition’s vendor-neutral product line, integrating its medical software applications into third-party systems. The deal was expected to close ye...
Source: Mass Device - July 19, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Imaging Mergers & Acquisitions Wall Street Beat royalphilips TomTec Source Type: news

Philips to acquire imaging software firm TomTec
Royal Philips has signed an agreement to acquire German imaging software developer...Read more on AuntMinnie.comRelated Reading: Philips partners on CT dose management initiative Philips, Varian, IBA partner on Singapore cancer center Philips to move MR-HIFU business to Profound TomTec nets FDA OK for new software TomTec launches cardiac visualization software at ACC TomTec launches online teaching tool (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 18, 2017 Category: Radiology Source Type: news

EDAP pulls FDA bid for Focal One, plans to resubmit with new data
Edap (NSDQ:EDAP) said today it withdrew the FDA 510(k) application for its next-gen high-intensity focused ultrasound Focal One device designed to treat prostate cancer. The French company said that following “advanced discussions” with the federal watchdog, it plans to submit a new 510(k) application which includes new clinical data. “As mentioned during our last quarterly call, a shift in biopsy protocol has created difficulties in comparing biopsy data under the current 510k application. We actively worked with some of our key users in Europe to gather new and additional clinical data on Foca...
Source: Mass Device - July 18, 2017 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Oncology Regulatory/Compliance Ultrasound EDAP TMS SA Source Type: news

Philips partners on CT dose management initiative
Royal Philips and West Physics are collaborating to create a CT radiation dose...Read more on AuntMinnie.comRelated Reading: Philips, Varian, IBA partner on Singapore cancer center Philips to move MR-HIFU business to Profound Philips buys catheter developer CardioProlific Philips to buy Spectranetics in $2.2B deal Philips lands FDA nod for new IntelliSpace applications (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 17, 2017 Category: Radiology Source Type: news

Philips, Varian, IBA partner on Singapore cancer center
Royal Philips plans to collaborate with Varian Medical Systems and Ion Beam...Read more on AuntMinnie.comRelated Reading: Philips to move MR-HIFU business to Profound IBA inks Va. installation deal Philips buys catheter developer CardioProlific FDA clears Varian's Halcyon rad therapy system IBA to show updated synthesizer at SNMMI 2017 Varian to build radiation oncology centers in Vietnam (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 12, 2017 Category: Radiology Source Type: news

Philips to move MR-HIFU business to Profound
Royal Philips has made an agreement to transfer its MR-guided high-intensity...Read more on AuntMinnie.comRelated Reading: Philips buys catheter developer CardioProlific Philips to buy Spectranetics in $2.2B deal Philips lands FDA nod for new IntelliSpace applications Philips relaunches Pioneer Plus IVUS catheter Philips launches new business intelligence software (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 6, 2017 Category: Radiology Source Type: news

Philips picks up peripheral thrombectomy device maker CardioProlific
Royal Philips (NYSE:PHG) last week said it paid an unspecified amount to acquire stealthy CardioProlific and the peripheral thrombectomy catheters it’s developing. Philips said the deal for Hayward, Calif.-based CardioProlific is complementary to its $2.16 billion acquisition of Spectranetics (NSDQ:SPNC) and its own line of image-guided therapies. “The acquisition of CardioProlific will further strengthen our innovation pipeline of catheter-based therapy devices,” image-guided therapy business leader Bert van Meurs said in prepared remarks. “We are convinced that the development of CardioP...
Source: Mass Device - July 5, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Catheters Mergers & Acquisitions cardioprolific peripheral royalphilips Source Type: news

Profound Medical to pay $6m for Philips ’ Sonalleve MR-HIFU biz
Profound Medical (TSX:PRN) said today that it agreed to put up about $6 million worth of its own shares to acquire the Sonalleve MR-HIFU business from Royal Philips (NYSE:PHG). Toronto-based Profound said the deal calls for it to put up 7.4 million shares at 84.9¢ (C$1.10) apiece, representing a 22% premium over its closing price yesterday. The total deal value is $6.3 million (C$8.1 million) The agreement also has earn-outs pegged to future revenues of 5% to 7% of Sonnalleve sales through 2020, the company said. Philips, which already sells Profound’s Tulsa-Pro prostate ablation system, also pledged t...
Source: Mass Device - June 30, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Imaging Mergers & Acquisitions Wall Street Beat Women's Health Profound Medical Inc. royalphilips Source Type: news

Theraclion partner UVA wins FDA nod for combined HIFU, immunotherapy breast cancer trial
Theraclion said yesterday its academic development partner, the University of Virginia, won  an FDA nod to launch a study of the combined use of echotherapy high intensity focused ultrasound and immunotherapy drug pembrolizumab for treating patients with breast cancer. The study will examine the combined treatment’s effect on fighting breast cancer tumor cells, the French company said. Theraclion is hopeful that HIFU treatment may locally potentiate immune responses induced by the immunotherapy drugs. Read the whole story at our sister site, Drug Delivery Business   The post Theraclion partner UVA wins FDA ...
Source: Mass Device - June 27, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Theraclion Source Type: news

Echotherapy: A Future Option for Benign Thyroid Nodule Symptoms? Echotherapy: A Future Option for Benign Thyroid Nodule Symptoms?
High-intensity focused ultrasound ablation, or echotherapy, of symptomatic but benign solid thyroid nodules is an emerging technology, available in a few clinics in Europe.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Theraclion touts Echopulse data from thyroid nodules studies
Theraclion (EPA:ALTHE) touted data today from 3 studies evaluating the use of Echopulse as a non-invasive treatment for benign thyroid nodules. One of the studies was the 1st direct comparison of echotherapy to surgery. The study, which was published in the International Journal of Hyperthermia, compared 43 patients who were treated with Theraclion’s Echopulse, an ultrasound-guided high-intensity focused ultrasound system, to 103 patients who underwent hemithyroidectomy. Patients who were treated with the French company’s system experienced significantly lower incidence of subclinical hypoth...
Source: Mass Device - May 24, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Surgical Ultrasound Theraclion Source Type: news

SonaCare points to new Medicare HIFU reimbursement code
High-intensity focused ultrasound (HIFU) developer SonaCare Medical said the...Read more on AuntMinnie.comRelated Reading: SonaCare debuts international HIFU prostate registry New HIFU center launches in Ohio SonaCare, Invivo team up for HIFU ablation tracking SonaCare lands FDA nod for HIFU system SonaCare teams up with Invivo (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 23, 2017 Category: Radiology Source Type: news

EDAP touts CMS reimbursement win for HIFU prostate ablation
Edap (NSDQ:EDAP) today touted that the Centers for Medicare & Medicaid Services established reimbursement billing codes for high intensity focused ultrasound ablation procedures for prostate tissue. The French company said that the new CMS C-code covering HIFU ablation of prostate tissue procedures will take effect July 1. The code will cover procedures performed by its HIFU devices, including whole primary gland prostate ablation, partial prostate ablation or whole and partial salvage ablation. “We are elated by CMS’s decision. This is another key milestone in the acceptance and recognition of HIFU te...
Source: Mass Device - May 22, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Ultrasound EDAP TMS SA Source Type: news

Insightec wins FDA nod for Exablate Neuro for use with 1.5T MRI
Insightec said today it won FDA approval for its Exablate Neuro model 4000 system, now cleared for use with 1.5 Tesla magnetic resonance imaging  for treating essential tumor in patients non-responsive to medication. The Exablate Neuro device uses high-intensity, focused ultrasound to thermally ablate targeted tissue, guided by continuous magnetic resonance imaging; the procedure can be performed non-invasively through an intact skull. “Being able to bring MR-guided focused ultrasound to hospitals that have 1.5T MRIs will enable more essential tremor patients to have access to this non-invasive treatme...
Source: Mass Device - May 9, 2017 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Neurological Regulatory/Compliance InSightec Ltd Source Type: news

Insightec touts 1st patient treated in Exablate Neuro FDA feasibility trial
Insightec today announced that the 1st patient has been treated in a feasibility trial exploring the use of its Exablate Neuro system for treating benign centrally-located intracranial tumors in pediatric and young adults. The Exablate Neuro device uses high-intensity, focused ultrasound to thermally ablate targeted tissue, guided by continuous magnetic resonance imaging; the procedure can be performed non-invasively through an intact skull. A team at the Nicklaus Children’s Hospital performed the 1st procedure on a 21-year old patient suffering from seizures associated with a benign hypothalamic hamartoma ...
Source: Mass Device - April 20, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Neurological InSightec Ltd Source Type: news

SonaCare debuts international HIFU prostate registry
High-intensity focused ultrasound (HIFU) technology developer SonaCare Medical...Read more on AuntMinnie.comRelated Reading: New HIFU center launches in Ohio SonaCare, Invivo team up for HIFU ablation tracking HIFU Prostate opens up Ohio treatment center HIFU Prostate Services signs Texas client SonaCare lands FDA nod for HIFU system (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 11, 2017 Category: Radiology Source Type: news

International Sonablate HIFU Prostate Registry Officially Launched
The HEAT Registry, with more than 1,500 patients, begins enrollment of U.S. patients CHARLOTTE, N.C., April 11, 2017 -- (Healthcare Sales & Marketing Network) -- SonaCare Medical, the leading developer and manufacturer of high intensity focused ultraso... Devices, Urology SonaCare Medical, Sonablate, HIFU, HEAT Registry (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 11, 2017 Category: Pharmaceuticals Source Type: news

Theraclion touts 2-year Echopulse data from breast fibroadenoma study
Theraclion (EPA:ALTHE) this week released 2-year results from a trial of its Echopulse non-invasive ultrasound system for treating breast fibroadenoma. Study results were published in the March 2017 issue of the Journal of Therapeutic Ultrasound, the French company said. The 20 patient study examined the use of the Echopulse system, an ultrasound-guided high-intensity focused ultrasound device, in reducing the volume of 26 breast fibroadenomas, or benign tumors. Data indicated that mean BFA volume was reduced by 77.32% after a single procedure and 90.47% after 2 procedures at 2 years. No cases of re-growth o...
Source: Mass Device - April 7, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Ultrasound Women's Health Theraclion Source Type: news

Scientists have discovered a way to destroy cancer tumors using nothing but sound waves
(Natural News) A recent breakthrough in high-intensity focused ultrasound therapy (HIFU) technology has proven its use as an effective cancer treatment. A multi-institutional research team from China developed a semi-enclosed, spherical cavity transducer that can produce a focused, standing-wave field with a subwavelength-scale focal region and extremely high ultrasound intensity. The spherical cavity transducer appeared to generate tighter... (Source: NaturalNews.com)
Source: NaturalNews.com - March 29, 2017 Category: Consumer Health News Source Type: news

New method heats up ultrasonic approach to treating tumors
High-intensity focused ultrasound (HIFU) is a breakthrough therapeutic technique used to treat tumors. The principle of this noninvasive, targeted treatment is much like that of focusing sunlight through a lens, using an ultrasonic transducer like a convex lens to concentrate ultrasound into a small focal region. Researchers have now designed a transducer for potential application in HIFU that can generate a steady, standing-wave field with a subwavelength-scale focal region and extremely high ultrasound intensity. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 28, 2017 Category: Science Source Type: news

New method heats up ultrasonic approach to treating tumors
(American Institute of Physics) High-intensity focused ultrasound (HIFU) is a breakthrough therapeutic technique used to treat tumors. The principle of this noninvasive, targeted treatment is much like that of focusing sunlight through a lens, using an ultrasonic transducer like a convex lens to concentrate ultrasound into a small focal region. Researchers have now designed a transducer for potential application in HIFU that can generate a steady, standing-wave field with a subwavelength-scale focal region and extremely high ultrasound intensity. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 28, 2017 Category: Cancer & Oncology Source Type: news

Hitting cancer with high-intensity ultrasound, immunotherapy
In a new study, researchers have shown that combining high-intensity focused ultrasound with two immunotherapies (a PD-1 checkpoint inhibitor and TLR9 agonist) can produce excellent response rates in mouse models of epithelial cancer. They also found that, for the combination to be effective, immunotherapies must come first. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 23, 2017 Category: Science Source Type: news

MRI-guided high-intensity focused ultrasound therapy for uterine fibroids has potential
(Institute for Quality and Efficiency in Health Care) IQWiG has attributed a potential for a benefit to a new treatment method according to § 137e SGB V. A testing study has been initiated. Numerous other assessments had no consequences. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 22, 2017 Category: Global & Universal Source Type: news

High-Intensity Focused Ultrasound for Focal Therapy High-Intensity Focused Ultrasound for Focal Therapy
Focal HIFU shows promise for the treatment of prostate cancer, but important questions remain.Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 27, 2017 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

First patients treated in pivotal trial for Theraclion ’ s Echopulse device
Theraclion (EPA:ALTHE) said today that the 1st patients were treated in the U.S. pivotal clinical trial evaluating the safety and efficacy of the company’s Echopulse echotherapy device as a non-invasive treatment for breast fibroadenomas. The clinical trial is slated to enroll 100 patients, the France-based company said, at 4 sites across the U.S. and 1 site in Germany. Patients will receive a single high-intensity treatment with Echopulse. The study’s primary endpoint is a reduction of fibroadenoma volume, pain and anxiety. “High intensity focused ultrasound (HIFU) technology is exciting because it ...
Source: Mass Device - February 9, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Imaging Oncology Wall Street Beat Theraclion Source Type: news

HIFU-Hemiablation for Treatment of Prostate Cancer? HIFU-Hemiablation for Treatment of Prostate Cancer?
Dr Gerald Chodak questions the value of the IDEAL study to evaluate HIFU-hemiablation as the primary treatment for prostate cancer.Medscape Urology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 31, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

FDA clears next-gen Sonablate prostate device from SonaCare
SonaCare Medical said today that it won 510(k) approval from the FDA for the latest version of its high intensity focused ultrasound prostate tissue ablation device. The Sonablate device was the 1st of its kind to receive regulatory approval for the focused ablation of prostate tissue, according to SonaCare. The next-gen version features a tool to quantify changes in tissue composition following treatment. It also boasts an altered delivery sequence in combination with an automated planning system that can reduce the overall procedure time by 40%, the Charlotte, N.C.-based company reported. “We worked diligently with...
Source: Mass Device - January 11, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: 510(k) Food & Drug Administration (FDA) Oncology Regulatory/Compliance Ultrasound SonaCare Medical Source Type: news

SonaCare Medical Granted FDA Regulatory Clearance for Updated HIFU Prostate Tissue Ablation Device
CHARLOTTE, N.C., Jan. 11, 2017 -- (Healthcare Sales & Marketing Network) -- SonaCare Medical, leading developer and manufacturer of high intensity focused ultrasound (HIFU) technologies, reports receipt of 510(k) regulatory clearance to market its latest ... Devices, Urology, FDA SonaCare Medical, Sonablate, HIFU (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 11, 2017 Category: Pharmaceuticals Source Type: news

Celsion ’ s ThermoDox activated by ultrasound in pediatric cancer study
Celsion (NSDQ:CLSN) and Children’s National Health System are teaming up to tackle refractory solid tumors in pediatric patients using a heat-activated chemotherapy drug and noninvasive ultrasound. The Phase I clinical trial, which launched last November, is the 1st of its kind in the U.S. Lawrenceville, N.J.-based Celsion’s ThermoDox is a heat-activated liposomal doxorubicin. In combination with MRI, high-intensity focused ultrasound is used to direct sound wave energy and heat the tumor. When the liposomal chemotherapy drug comes into contact with the heated tumor, the liposome changes structur...
Source: Mass Device - January 6, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Pediatrics Celsion Children's National Health System Source Type: news

Parkinson's UK comments on the first non-invasive ultrasound that can help patients with tremors
Claire Bale, Head of Research Communications and Engagement at Parkinson's UK, comments on Imperial College Healthcare NHS trust using high-intensity, focused ultrasound waves for the first time in... (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - December 12, 2016 Category: Neurology Tags: Parkinson's Disease Source Type: news

New trial will assess MR-HIFU, chemo drug combo
The Children's National Health System in Washington, DC, and oncology drug...Read more on AuntMinnie.comRelated Reading: FDA OKs InSightec's MRgFUS tremor treatment device New HIFU center launches in Ohio SonaCare, Invivo team up for HIFU ablation tracking Prostate HIFU available for 1st time in U.S. SonaCare lands FDA nod for HIFU system (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 16, 2016 Category: Radiology Source Type: news

Pricey New Treatment Roils Issues of How to Treat Prostate Cancer Pricey New Treatment Roils Issues of How to Treat Prostate Cancer
High-intensity focused ultrasound, often not covered by insurance, leads to discussions about which patients benefit in the real world.Kaiser Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 6, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

SonaCare Medical Paves the Way with the First HIFU Device Cleared by the FDA for Prostate Tissue Ablation - A Year in Review
CHARLOTTE, N.C., Oct. 5, 2016 -- (Healthcare Sales & Marketing Network) -- SonaCare Medical, leading developer and manufacturer of High Intensity Focused Ultrasound (HIFU) Technologies, reports over 40 acquisitions of Sonablate® technology since the d... Devices SonaCare Medical, Sonablate, HIFU (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 5, 2016 Category: Pharmaceuticals Source Type: news

Insightec inks ExAblate co-development deal with Siemens
Insightec said today it inked a collaborative strategic deal with Siemens Healthineers (NYSE:SI) to develop compatibility between Insightec’s Exablate Neuro system and Siemens Magnetom Aera and Skyra 1.5 Tesla and 3T clinical MRI systems. The companies said the agreement will expand Siemens diagnostic imaging portfolio and will allow existing and future Siemens MRI customers access to the Exablate Neuro system. “Our agreement with Siemens Healthineers will allow us to significantly expand Exablate Neuro’s market presence. Siemens has embraced our technology and together we will bring our therapy...
Source: Mass Device - August 15, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Neurological InSightec Ltd Siemens Healthineers Source Type: news

MassDevice.com +5 | The top 5 medtech stories for July 11, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. FDA approves Insightec’s Exablate Neuro focused ultrasound device The FDA said today that it approved the Exablate Neuro device made by Insightec for treating essential tremor in patients who don’t respond to drug t...
Source: Mass Device - July 11, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

FDA approves Insightec’s Exablate Neuro focused ultrasound device
The FDA said today that it approved the Exablate Neuro device made by Insightec for treating essential tremor in patients who don’t respond to drug therapy. The Exablate Neuro device uses high-intensity, focused ultrasound to thermally ablate targeted tissue, guided by continuous magnetic resonance imaging; the procedure can be performed non-invasively through an intact skull. Essential tremor can be treated with beta blockers or anti-convulsant drugs, but some patients don’t respond to drug treatment, the federal safety watchdog said. A surgical treatment called thalamotomy or deep-brain stimulation can a...
Source: Mass Device - July 11, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Imaging Neurological Regulatory/Compliance InSightec Ltd Source Type: news

First Prostate Cancer Patients Treated with HIFU Technology
Cordell Nwokeji, MD and Don Berardinucci, MD perform first Sonablate HIFU treatments in Houston, Texas at Houston Metro Urology in partnership with HIFU Prostate Services (Source: Disabled World)
Source: Disabled World - May 25, 2016 Category: Disability Tags: Prostate Cancer Source Type: news